## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.2% below STRENGTH zone (4.0-10.0%); PEG 4.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($82.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Barclays Adjusts Price Target on Edwards Lifesciences to $103 From $99, Maintains Overweight Rating**
- Source: marketscreener.com | 20251205T120437 | Somewhat-Bullish | Relevance: 100%
- Barclays has increased its price target for Edwards Lifesciences (EW) from $99 to $103, while reaffirming an "Overweight" rating on the stock. This adjustment reflects continued analyst confidence in the medical technology company. The article also notes similar price target adjustments from other firms like RBC, Stifel, BTIG, and Wells Fargo, indicating broad analyst attention to Edwards Lifesciences.

**2. Edwards Lifesciences (NYSE: EW) targets 2026 EPS of $2.80-$2.95 with TMTT up 35%-45%**
- Source: Stock Titan | 20251204T140813 | Bullish | Relevance: 100%
- Edwards Lifesciences outlined its patient-focused strategy and financial guidance, projecting 2026 constant currency sales growth of 8%-10% to $6.4-$6.8 billion and adjusted EPS of $2.80-$2.95. The company expects significant growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) sales, targeting 35%-45% constant currency growth. Edwards is focusing on advancing structural heart therapies, including TAVR, TMTT, surgical innovations, and pioneering new areas like Structural Heart Failure and TAVR-AR.

**3. OMERS ADMINISTRATION Corp Boosts Stock Holdings in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251203T124745 | Somewhat-Bullish | Relevance: 100%
- OMERS ADMINISTRATION Corp significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 97.3%, acquiring an additional 21,950 shares. This boosted their total holdings to 44,504 shares valued at $3.48 million, contributing to institutional investors owning 79.46% of the stock. Meanwhile, company insiders have recently been selling shares, with the VP selling 1,020 shares and the CFO selling 13,000 shares.

**4. Edwards Lifesciences (EW): Stifel Raises Price Target to $100**
- Source: GuruFocus | 20251205T181220 | Bullish | Relevance: 100%
- Stifel analyst Rick Wise has maintained a 'Buy' rating on Edwards Lifesciences (EW) and increased the price target from $95.00 to $100.00, indicating a positive outlook for the company. This follows a trend of positive adjustments from other analysts, reinforcing investor confidence. Edwards Lifesciences, a leader in medical devices for structural heart disease, derives significant sales from outside the US.

**5. Edwards Lifesciences (EW): Stifel Raises Price Target to $100**
- Source: GuruFocus | 20251205T180806 | Bullish | Relevance: 100%
- Stifel has maintained its 'Buy' rating for Edwards Lifesciences (EW) and increased the price target from $95.00 to $100.00, reflecting a positive outlook for the company. This follows a trend of positive ratings adjustments from multiple analysts, reinforcing investor confidence. Edwards Lifesciences, a leader in medical devices for structural heart disease, derives significant sales from outside the US.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Canaccord Genui | $89 | $84 | +6% |
| 2025-12-05 | Stifel | $100 | $95 | +5% |
| 2025-12-05 | UBS | $92 | $90 | +2% |
| 2025-12-05 | Wells Fargo | $96 | $95 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Canaccord Genui | main | Hold |
| 2025-12-05 | Stifel | main | Buy |
| 2025-12-05 | UBS | main | Neutral |
| 2025-12-05 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.9x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 8 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 4.86 signals overvaluation risk, limited margin of safety. Forward P/E 30.0x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $51.0B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.86 |
| Forward P/E | 30.0 |
| Current P/E | 33.4 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: -DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.24% (CS: 44) | Neutral |
| RSI_14 | 59.1 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.123x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $86.19
- **Stop Loss:** $82.45 (4.3% risk)
- **Target:** $89.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 133
- **Position Value:** $11,463.27
- **Portfolio %:** 11.46%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*